RCKT Stock Summary and Trading Ideas (Rocket Pharmaceuticals | NASDAQ:RCKT)

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals trades on the NASDAQ stock market under the symbol RCKT.

As of January 14, 2026, RCKT stock price climbed to $3.96 with 1,732,590 million shares trading.

RCKT has a beta of 1.73, meaning it tends to be more sensitive to market movements. RCKT has a correlation of 0.07 to the broad based SPY ETF.

RCKT has a market cap of $428.56 million. This is considered a Small Cap stock.

Last quarter Rocket Pharmaceuticals reported $0 in Revenue and -$.45 earnings per share. This fell short of revenue expectation by $-250,000 and exceeded earnings estimates by $.05.

In the last 3 years, RCKT traded as high as $32.53 and as low as $2.19.

The top ETF exchange traded funds that RCKT belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

RCKT has underperformed the market in the last year with a return of -62.0%, while the SPY ETF gained +19.8%. In the last 3 month period, RCKT fell short of the market, returning -7.3%, while SPY returned +4.5%. However, in the most recent 2 weeks RCKT has outperformed the stock market by returning +12.8%, while SPY returned +1.2%.

RCKT support price is $3.64 and resistance is $3.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCKT shares will trade within this expected range on the day.